
Supplementary Figure 1. Indexes at the start and after 3 months of nilotinib therapy. (A) HOMA2-IR index [reflecting hepatic insulin resistance]; (B) Insulin sensitivity index (HOMA2-%S) derived from the HOMA2 calculation as percentages of a normal reference population; (C) ISI_{0.120} or Gutt index [tends to reflect peripheral insulin resistance and correlates with euglycemic clamp]; (D) Steady state **β-cell function** (HOMA2-%B) derived from HOMA2 as percentages of a normal reference population.

Supplementary Figure 2. Change in β -cell function based on the HOMA2-%B difference (HOMA2-%B _{3month} – HOMA2-%B_{start}) at the start and the 3rd month of nilotinib therapy in 2 patients who fulfilled criteria of diabetes mellitus (DM) during nilotinib treatment compare to the 8 other patients.

Supplementary Figure 1.



Supplementary Figure 2.

